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Objectives. The action of mexiletine on diseased myocardium
was assessed in reentrant ventricular tachycardia (VT).
Background. Whether class Ib antiarrhythmic agents exert a
preferential action on the central common pathway of reentrant
ventricular tachycardia has not yet been studied in humans.
Methods. In 10 consecutive patients (7 with a previous myocar-
dial infarction, 3 with nonischemic disease), VT was induced and
entrained with rapid pacing. The orthodromic conduction time
was measured from stimulus to the entrained electrogram at the
exit from the presumed central common pathway (i.e., the earliest
site of activation). Mexiletine at 125 to 250 mg was administered
intravenously, and when VT with the same conﬁguration was
induced, the study was repeated. The action of mexiletine on the
central common pathway was assessed from the changes in VT
cycle length and orthodromic conduction time. The effects on QRS
complex duration, local conduction time between the exit and the
pacing site and duration of the local electrogram were compared
between normal and diseased myocardium.
Results. Mexiletine prolonged the VT cycle length in all pa-
tients, from (mean  SD) 316  30 to 360  64 ms (mean change
20  7%, p < 0.001); during entrainment of VT, the orthodromic
conduction time was prolonged, from 306  58 to 367  89 ms
(mean change 18  9%, p < 0.001). These changes were highly
correlated (r 0.95, p < 0.001). QRS duration changed little (4
3%), and local conduction time showed no change. The duration of
the fragmented electrogram width was prolonged by mexiletine:
from 146  50 to 176  56 ms (mean change 23  8% during VT,
p < 0.001). Only a slight change occurred in the effective
refractory period, both at the pacing site and at the exit.
Conclusions. Mexiletine caused little change in conduction time
in normal myocardium but prolonged VT cycle length, ortho-
dromic conduction time and duration of the local electrogram at
the earliest site of activation of VT. From these ﬁndings, a
preferential action of mexiletine on diseased myocardium was
suggested but seemed to occur only at higher frequencies during
tachycardia.
(J Am Coll Cardiol 1996;28:1759–64)
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Procainamide has been shown to prolong the duration of the
fractionated electrogram (1,2) and to preferentially depress
conduction velocity within the reentrant circuit in human
ventricular tachycardia (VT) (3). In contrast, the effects of
mexiletine on the fractionated electrogram as well as on
electrically abnormal myocardium have been reported to be
negligible (1,4). These negative ﬁndings could be related to the
absence of partial diastolic depolarization in the myocardium
as the basis of slowed conduction (1,5) or, because the action
of the drugs was studied during sinus rhythm, to fast dissocia-
tion from sodium channels (6–8). Another reason could be
that sodium channel blockade and depression of conduction
are relatively mild after mexiletine administration. One study
(9) showed a preferential depression of conduction in the
diseased myocardium by mexiletine but whether the site was
related to the origin of VT was not deﬁned.
In the present study, the action of mexiletine on the central
common pathway and on the electrically abnormal electrogram
were determined and compared with that in normal myocar-
dium. Evidence of a preferential action of mexiletine on the
slow pathway was revealed.
Methods
Patients. Ten consecutive patients (mean [SD] age 56 
18 years, range 21 to 72; six men, four women) underwent
serial drug testing for selection of antiarrhythmic agents for
symptomatic monomorphic sustained VT. They fulﬁlled the
following criteria for inclusion: 1) the same monomorphic
sustained VT was inducible at the control study and after
administration of mexiletine; 2) the site of VT origin was
mapped by the endocardial catheter technique (10,11); and 3)
VT was able to be entrained with rapid ventricular pacing at
progressively shorter cycle lengths.
Old myocardial infarction (6 months after acute myocar-
dial infarction) was found in seven patients in whom an
occluded coronary artery to the infarction area was demon-
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strated by coronary arteriography. Left ventricular ejection
fraction by left ventriculography was 0.43  0.11. Two patients
had idiopathic dilated cardiomyopathy, but left ventricular
ejection fraction was 0.40. The remaining patient had under-
gone operation for double-outlet right ventricle 10 years
previously and had normal left ventricular ejection fraction.
Electrophysiologic study. After a detailed explanation of
the procedures, purpose and possible risks, written informed
consent was obtained, and electrophysiologic studies were
performed in the nonsedated and postabsorptive states, as
reported earlier (11,12). Antiarrhythmic agents were discon-
tinued 2 to 3 days before the control study, and no patient had
been receiving amiodarone.
Three quadripolar electrode catheters with an interelec-
trode distance of 5 mm were introduced from the femoral vein
and placed at the high right atrium, the His bundle recording
region and the apex of the right ventricle. The electrode
catheter in the right atrium was moved to the outﬂow tract of
the right ventricle when necessary. Another catheter was
placed in the left ventricle. They were used for stimulation and
recording. Electrical stimuli were delivered at twice the late
diastolic threshold and 2 ms of the width through a program-
mable stimulator (cardiac stimulator model BCO2, Fukuda
Denshi Co., Tokyo, Japan).
Bipolar intracavitary electrograms were ﬁltered at 30 to
500 Hz and recorded with three surface electrocardiographic
(ECG) leads: I, II and V1 on a strip chart at a paper speed of
100 or 200 mm/s (Mingograf 7, Siemens-Elema Co., Solna,
Sweden). They were also stored on magnetic tape (cassette
recorder model XR-5000, TEAC, Tokyo, Japan) and retrieved
later for use on a thermal recorder (thermal recorder model
RF-85 Fukuda Denshi Co.).
All induced arrhythmias were recorded on 12-lead ECGs
and used for analysis of VT conﬁguration.
Catheter mapping and rapid pacing of VT. Extensive
endocardial mapping (10,11) was performed to localize the site
of earliest activation during VT. The local electrogram at the
site should precede the onset of the QRS complex of VT, and
pace mapping at the site should result in QRS complex
conﬁgurations identical or nearly identical to that of VT. The
site of earliest activation of VT was presumed to be close to the
exit from the central common pathway of the reentrant circuit,
and the conduction time from the stimulus to the entrained
electrogram at this site was assumed to represent orthodromic
conduction, as described later.
Rapid pacing was then performed at a cycle length 10 to
20 ms shorter than that of the VT, and if the VT was entrained,
rapid pacing was repeated at progressively shorter cycle
lengths after a decrement in cycle length of 10-ms steps until
interruption of VT (11,12). Rapid pacing was ﬁrst attempted at
the apex of the right ventricle, and when VT was unable to be
entrained, rapid pacing was performed at the second or third
site from the right ventricular outﬂow tract or from the left
ventricle, respectively.
According to the criteria of classical transient entrainment
by earlier researchers (17,18), we used 1) demonstration of
constant fusion during rapid pacing except for the last captured
beat that occurred at the pacing rate in the surface ECG or
intracavitary electrogram; 2) demonstration of progressive
fusion at shorter paced cycle lengths; 3) interruption of VT
with localized block to the site of the exit, followed by
activation from a different direction with a shorter conduction
time. In addition, another criterion was used when an elec-
trode catheter was located within the central common path-
way: 4) Rapid pacing at the site resulted in concealed entrain-
ment (13–16).
Mexiletine administration. After the control study, mexil-
etine was administered intravenously at a dosage of 125 to
250 mg in 10 to 15 min. Electrode catheters were positioned at
exactly the same sites during the administration of mexiletine,
and the electrophysiologic variables were measured. A main-
tenance dose was not given, and plasma levels were not
measured.
Rationale and data analysis. Because details of the reen-
trant circuit were not available, the reentrant circuit was
assumed to be represented by a ﬁgure-eight model in which the
central common pathway is separated by anatomic or func-
tional block (Fig. 1).
In this model of VT, mexiletine acts on the slowly conduct-
Abbreviations and Acronyms
ECG  electrocardiogram
VT  ventricular tachycardia
Figure 1. Schema of VT and conduction times. The reentrant circuit
of VT is represented by the ﬁgure eight model. The entrance (Ent) to
the central common pathway (CCP) may be unknown, but the exit
(Exit) can be approximately determined as the site of the earliest
activation by endocardial mapping. As long as the VT conﬁguration
remains unchanged, the exit is assumed to be spatially ﬁxed. During
VT, the wave fronts proceed to the outer loop with the conduction
time (d) and the central common pathway with the conduction time
(b). During transient entrainment, the orthodromic conduction time to
the exit is the sum of the conduction time from the pacing site (P) to
the entrance (undeﬁned) (a) and then to the exit (b). The local
conduction time (c) is deﬁned as that from the exit to the pacing site.
The drug-induced change in the central common path is reﬂected in
the orthodromic conduction time (a  b) as well as in the VT cycle
length (b  d). Mex  mexiletine.
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ing central common pathway and on the normal myocardium
outside the slow pathway. The action on the central common
pathway can be assessed from changes in the cycle length of
VT (Fig. 1 [b d]) and from the orthodromic conduction time
(Fig. 1 [a  b]), which is measured from the pacing stimulus to
the local electrogram at the exit, whereas the action on the
normal myocardium can be assessed by analysis of changes in
the local conduction time (Fig. 1 [c]), which is measured from
the initial deﬂection of the electrogram at the exit to that of the
pacing site during VT.
QRS duration was measured from the onset of the initial
deﬂection to the terminal deﬂection and was used as an index
of global intraventricular conduction. It was conﬁrmed that the
stimulus-local ventricular electrogram did not change.
The duration of the local electrogram was measured from
the onset of the initial deﬂection to the terminal deﬂection in
3 consecutive beats at a paper speed of 100 mm/s, and the
average was used as an index of localized myocardial conduc-
tion. A beat to beat variance was essentially not observed. The
duration of the local electrogram was measured during sinus
rhythm and VT.
The amplitude of the local electrogram was also measured
as the peak to peak deﬂection and was measured at the exit
(diseased myocardium) and at the pacing site (normal myocar-
dium).
The effective refractory period was measured at the exit and
at the pacing site (normal myocardium) as the longest coupling
interval of the extrastimulus that failed to capture the myocar-
dium at a basic cycle length of 400 ms. The effective refractory
period was measured soon after termination of VT.
These variables were measured before and after mexiletine
during VT identical in conﬁguration to that at the control state.
Ventricular tachycardia conﬁguration was veriﬁed by a 12-lead
ECG and the constant conﬁguration and duration of the
intracavitary electrograms. The measurements were repeated
during reinduced VT and ended 15 to 30 min after completion
of mexiletine administration.
Results are presented as mean value  SD. The t test was
used for paired samples and p  0.05 was considered signiﬁ-
cant.
Results
Effect of mexiletine on VT cycle length and orthodromic
conduction time. After mexiletine, the VT cycle length was
prolonged (from 316  30 to 360  64 ms, mean change 20 
7%) and was signiﬁcant (p  0.002). Ventricular tachycardia
induced after mexiletine showed a conﬁguration nearly iden-
tical to that during the control state.
Rapid pacing during VT. All VTs were entrained with
rapid pacing from the right ventricular apex in eight patients
and from the right ventricular outﬂow tract in two and
performed from the same site in before and after mexiletine
(Fig. 2 and 3). As the paced cycle length decreased, the
orthodromic conduction time showed a frequency-dependent
prolongation in eight patients but was ﬂat in two. In 9 of 10
patients, VT was terminated at a critical cycle length of 255 
35 and 301  55 ms before and after mexiletine, respectively
(mean change 22  13%), with a signiﬁcant prolongation (p 
0.002). The zone of entrainment (VT cycle length minus
VT-interrupting paced cycle length) was unchanged: 66  22
and 66 44 ms before and after mexiletine, respectively. In the
remaining patient, rapid pacing was stopped before termina-
tion.
The orthodromic conduction time that was obtained at the
paced cycle length and was closest to the VT cycle length was
306  58 ms in the control study and was prolonged to 367 
89 ms (mean change 18  9%) after administration of mexil-
etine. The change in VT cycle length was highly corre-
Figure 2. Changes in VT cycle length and orthodromic
conduction time before and after mexiletine administra-
tion. Electrocardiographic tracings from a patient who
developed monomorphic VT in the chronic stage after
repair of double-outlet right ventricle. A, In the control
state, VT had a cycle length of 270 ms, and rapid pacing
from the apex of the right ventricle (RVA) was able to
entrain the VT. The orthodromic conduction time was
measured from the pacing stimulus to the earliest deﬂec-
tion of the local electrogram at the right ventricular
outﬂow tract (RVO) as denoted by arrows: 220 ms. Rapid
pacing was repeated at shorter cycle lengths after one
decrement in steps of 10 ms, and VT was interrupted with
rapid pacing at a critical cycle length (not shown). B, After
mexiletine administration, the VT cycle length was pro-
longed to 310 ms, and rapid pacing from the same site was
able to entrain and terminate the VT. The orthodromic
conduction was prolonged to 260 ms. However, the time
interval between the earliest deﬂection of the local elec-
trogram at the right ventricular outﬂow tract to the pacing
site (RVA) was unchanged: 80 ms before and after
mexiletine. The width of the local electrogram at the right
ventricular outﬂow tract was widened from 115 to 135 ms.
1761JACC Vol. 28, No. 7 AIZAWA ET AL.
December 1996:1759–64 ACTION OF MEXILETINE ON REENTRANT CIRCUIT
lated with that in orthodromic conduction time, as shown in
Fig. 4 (r  0.95, p  0.001).
Effect of mexiletine on local electrogram. The site of the
earliest activation of VT showed abnormal results on the
electrogram: 1.2  0.6-mV amplitude and 146  50-ms
duration (Fig. 2 and 3). Pacing during sinus rhythm at this site
resulted in a QRS conﬁguration identical to that of VT,
whereas pacing during VT resulted in acceleration in response
to the pacing rate without any change in the QRS conﬁgura-
tion.
After administration of mexiletine, the duration of the local
electrogram during VT was prolonged to 176  56 ms (p 
0.001; mean change 23  8%). However, electrogram prolon-
gation was not correlated with prolongation of VT cycle length
(Fig. 4). The mexiletine-induced change in duration of the
local electrogram was not signiﬁcant when measured during
sinus rhythm (124  54 vs. 125  54 ms).
The pacing site showed normal electrograms (3.8 0.9-mV
amplitude, 52  8-msec duration), and they showed little
change after administration of mexiletine during VT as well as
during sinus rhythm (53  8 ms).
Effect of mexiletine on local conduction time and QRS
duration. During VT, the local conduction time from the exit
to the pacing site was 55  26 ms and changed little after
administration of mexiletine (58  22 ms, p  NS). During
VT, QRS duration was 154  26 ms in the control state and
was prolonged to 161 27 ms after mexiletine; the change was
small (4  3%) but statistically signiﬁcant (p  0.05). During
sinus rhythm, QRS duration showed little change (120 48 vs.
127  55 ms, p  NS).
Effect of antiarrhythmic drugs on effective refractory pe-
riod. The effective refractory period was 240  21 and 253 
12 ms at the pacing site and at the site of VT origin,
respectively and did not change signiﬁcantly after administra-
tion of mexiletine (238 22 and 245 11 ms, respectively, p
NS).
Discussion
Mechanism of VT. All VT in the present study was initi-
ated and terminated with electrical stimulation and, further-
more, VT could be entrained with rapid ventricular pacing
(11,12,17,18). When VT was interrupted at a critical paced
cycle length, the site of the earliest activation was activated
from a different direction and at a shorter timing, which
suggests the presence of slow conduction (18). All these
ﬁndings strongly suggest that the mechanism of VT is reentry.
Although some patients in the present study had VT
unrelated to coronary disease, the mechanism of VT is most
likely reentry with an excitable gap (19,20).
Action of mexiletine on central common pathway. Because
mexiletine was administered after termination of VT, we did
not determine whether mexiletine was able to terminate VT.
Therefore, we described the electrophysiologic effects in VT in
cases where mexiletine did not produce any antiarrhythmic
response, and we did not attempt to explain the mechanism by
which mexiletine might terminate VT or prevent induction in
patients with that response.
Figure 4. Relation between changes in VT cycle length (d-VTCL) and
orthodromic conduction time (d-St-Ex) and duration of fragmented
electrogram (d-Frag). A positive correlation was observed between
changes in orthodromic conduction time and VT cycle length (top).
However, the change in duration of the fragmented activities at the
exit was not correlated with changes in VT cycle length (bottom).
Figure 3. Effects of mexiletine on VT, conduction time and local
electrogram. Top, During VT with a cycle length of 360 ms, rapid
pacing was able to entrain VT, and the orthodromic conduction time
was 290 ms. Bottom, After mexletine, the VT cycle length and the
orthodromic conduction time were prolonged to 400 and 340 ms,
respectively. The return cycle at the pacing site was 375 and 420 ms,
respectively. LV  left ventricle; other abbreviations as in Figure 2.
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The action of antiarrhythmic agents on the central common
pathway may be assessed indirectly by observing changes in VT
cycle length or more directly by changes in orthodromic
conduction time during transient entrainment of VT (Fig. 1).
Kay et al. (3) observed a correlation between changes in VT
cycle length and that of orthodromic conduction time to the
exit of VT before and after the administration of procain-
amide, but such was not observed between the VT cycle length
and the direct (antidromic) conduction time to the exit. This
ﬁnding was interpreted to represent a preferential action of
procainamide on the slow pathway of the reentrant circuit. A
similar ﬁnding was observed using mexiletine in the present
study, and a preferential action of the drug on the central
common pathway was shown.
Mexiletine and local electrogram. The site at which VT
originates has been shown (21,22) to consist of viable myocar-
dium with poor cell to cell coupling, the basis for slow
conduction (23,24), and such sites might show abnormal results
on electrograms (12,23).
Class Ia antiarrhythmic agents have been shown to prolong
the duration of the fragmented electrogram recorded during
electrophysiologic study (1) or to prolong the late potential in
the signal-averaging surface electrocardiogram (4), but the
effect of class Ib agents has been shown to be negligible. In the
present study, signiﬁcant prolongation was observed in the
electrogram of the diseased myocardium (at the exit), but not
in the normal myocardium (the pacing site), after administra-
tion of mexiletine.
The different results between our study and previous studies
(1,4) may be partly due to the fact that we measured the
mexiletine-induced changes during VT at higher rates, whereas
previous investigators studied the effects of mexiletine during
sinus rhythm (1,4). Because of the fast kinetics of mexiletine,
drug-induced changes might be negligible at lower rates (6–
8,25).
Mexiletine prolonged the duration of the fragmented elec-
trogram, but the change was not correlated with that of the VT
cycle length. This ﬁnding might suggest that the property of the
central common pathway is not homogeneous.
Limitations of the study. The small number of patients and
the varying underlying heart disease were limitations. How-
ever, all VTs were entrained and interrupted at a critical paced
cycle length with rapid ventricular pacing, and mechanism is
most likely reentry with an excitable gap.
Conduction time through the normal myocardium is in-
cluded in the orthodromic conduction time (a  b in Fig. 1),
and the exit might contain some diseased tissue, which would
affect local conduction time (c in Fig. 1). However, the latter
changed little, and the change in VT cycle length or ortho-
dromic conduction time caused by mexiletine was greater and
must be due to changes in the central common pathway.
Due to slowing of the VT rate by mexiletine, some variables
were not measured at exactly the same rate, but it seems
unlikely that we overestimated the drug-induced changes in
orthodromic conduction time or duration of fragmented elec-
trograms. These changes would have been greater had we
compared them at the same rate.
Conclusions. Signiﬁcant prolongation was observed in VT
cycle length and orthodromic conduction time through the
central common pathway after the administration of mexil-
etine. These changes were highly correlated. However, local
conduction time through the presumed normal myocardium
and QRS duration showed little change. From these ﬁndings, a
preferential action of mexiletine on diseased myocardium close
to the central common pathway was suggested but was re-
vealed at a higher heart rate.
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